Sheila Jacobs

All articles by Sheila Jacobs

• Researchers call for equity in global health policies to reduce HDFN

  In a recent review, researchers highlighted the causes of HDFN and how treatment can be improved across the globe.

• Case report: Managing alloimmunization during pregnancy leads to better outcomes in HDFN

  A recently published case study highlights the importance of early intervention in alloimmunized pregnancies to prevent HDFN complications.

• K-negative pregnancy results in healthy baby following preventative treatment

  A recent case study described a K-negative pregnant patient who was successfully treated with therapeutic plasma exchange and intravenous immunoglobulin.

• Filtered sunlight phototherapy safe, effective in newborns

  A recent study found filtered-sunlight phototherapy is safe and not inferior to intensive electric phototherapy to treat hyperbilirubinemia.

• Transfusions for minor blood groups vital to improve outcomes in HDFN

  A recent analysis HDFN linked to Kell incompatibility showed women may benefit from increased access to blood transfusions for minor blood groups.

• Novel RHD allele identified through routine blood donor testing

  A novel RHD allele has been identified during routine D typing performed among all potential blood donors in China.

• Genotyping may optimize limited blood supplies for transfusions

  A recent analysis showed that during critical blood shortages, specific tests may show a patient’s risk of negative transfusion reactions.

• Non-invasive screening method accurately predicts fetal anemia

  A recent study showed the MCA-PSV screening method could be an alternative to more invasive methods to predict fetal anemia.

• Study shows neutropenia in HDFN carries relatively low risk

  Researchers of a recently published study found neutropenia is primarily a benign and self-limiting condition in neonates with HDFN.

• Anti-D Ig recommended within 10 days of potential sensitization

  A recently published report stated that administering anti-D immunoglobulin (Ig) within 10 days of sensitization could prevent HDFN.